Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsTOPICALGeneric

ERYTHROMYCIN

ERYTHROMYCIN

Standard Dose
2%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued

Key Takeaways

  • Primary indication: Review priority: STANDARD Marketing status: Discontinued
  • Approval overview ERYTHROMYCIN is listed in Drugs@FDA under application 208100 (ANDA).
  • Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength SOLUTION;TOPICAL - 2% Sponsor PAI HOLDINGS PHARM Submission history Latest submission status date: 2017-11-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview ERYTHROMYCIN is listed in Drugs@FDA under application 208100 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ERYTHROMYCIN Form and strength SOLUTION;TOPICAL - 2% Sponsor PAI HOLDINGS PHARM Submission history Latest submission status date: 2017-11-20 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.